Author: biocytogen

Webinar: Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery

June 1, 2022

Our webinar “Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery” was live on June 22, 2022 at 1PM EDT. In this webinar, we Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate […]

Read More

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022

Beijing, China, May 24, 2022 /PRNewswire/ — Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and virtually from June 3-7, 2022. The posters describe updates from two phase I clinical studies […]

Read More

HBHL Symposium 2022

May 18, 2022

Attend the meeting Talk to us Healthy Brains, Healthy Lives (HBHL) is an interdisciplinary program, built on McGill’s global leadership in interdisciplinary neuroscience, that uses big data analysis to reveal the fundamental mechanisms underlying normal brain function and brain disorders. HBHL aims to accelerate translational discoveries and create a global centre of excellence in neuroinformatics […]

Read More

15th Canadian Neuroscience Meeting

May 11, 2022

Attend the meeting Talk to us at Tabletop T08 The Canadian Association for Neuroscience (CAN) is the largest association of neuroscientists in Canada. Our members dedicated to advancing brain research. Our association is composed of over one thousand researchers, who work at academic institutions across the country. We share the common goal of ensuring neuroscience […]

Read More

Immunology 2022

May 4, 2022

Poster Session Poster number: P620 Title: RenMice™ HiTS Platform Enables Identification of Novel Therapeutic Antibodies Date: Sunday, May 8, 2022 Time: 2:30 PM – 3:45 PM PDT Presenter: Jenna Frame, PhD, Scientific Communications & Marketing, Biocytogen Boston Attend the meeting Agenda Talk to us at booth 237! The largest annual immunology event worldwide, the AAI annual […]

Read More

Biocytogen Enters into Antibody Agreement with Merck

April 29, 2022

BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date […]

Read More

Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene

April 25, 2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite® mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs. RenMab™ and RenLite® mice, which have proprietary intellectual property rights, were developed by […]

Read More

PEGSBoston 2022

April 21, 2022

Speaker: Dr. Qingcong Lin, CEO, Biocytogen Boston Corporation, Biocytogen Boston Corp Time: 9:30 am EDT, May 2nd Talk title: Generation of Fully Human Antibodies for HLA-Peptide Complexes Using HLA Transgenic RenMice Session details: The in vivo complexity of B cell differentiation, selection, and affinity maturation cannot be recapitulated in vitro. To facilitate therapeutic antibody discovery, […]

Read More

Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers

April 18, 2022

BEIJING and SHANGHAI, April 18, 2022/PRNewswire/–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as “Biocytogen”) announced a collaboration agreement with CtM Biotech (Shanghai) Co., Ltd (hereafter referred to as “CtM Bio”) to jointly develop innovative antibody drugs against intracellular tumor-associated antigens. Under this agreement, Biocytogen will be responsible for screening fully human antibodies against specific […]

Read More

Webinar: Generation and discovery of high affinity antibodies

April 11, 2022

Our webinar “Generation and discovery of high affinity antibodies” was live on April 27, 2022 at 1PM EDT. In this webinar, we will Introduce Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provide proof-of-concept data supporting the robust capabilities of […]

Read More

Back to top